Get startedLog in
    Picture of Aytu Biopharma logo

    AYTU — Aytu Biopharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapContrarian
    All News

    Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

    Picture of Aytu Biopharma logoAytu Biopharma
    15/05/2025 03:41
    Aytu Biopharma Inc AYTU.OQ reported quarterly adjusted earnings of 21 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -52 cents.  The lone analyst forecast for the quarter was for a loss of 17 cents per share.

Revenue rose 2.6% to $18.45 million from a year ago; analysts expected $13.74 million.

Aytu Biopharma Inc shares had risen by 9.2% this quarter and lost 22.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00

This summary was machine generated from LSEG data May 15 at 02:41 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Mar. 31 2025-0.170.21Beat
    Dec. 31 2024-0.28-0.26Beat
    Sep. 30 2024-0.340.44Beat
    Jun. 30 2024-0.45-0.82Missed

    Recent news on Aytu Biopharma

    See all news